Asthma is common in the general population, including those in the workforce. Work exposures can cause or exacerbate asthma and can also be associated with asthma variants (e.g., eosinophilic bronchitis and aluminum potroom asthma) as well as symptoms that mimic asthma (e.g., the irritable larynx syndrome). In addition, even non–work-related asthma can affect the ability to work. This review focuses on current data about occupational asthma, defined as asthma due to conditions attributable to work exposures and not to causes outside the workplace.

One important and common subtype of work-related asthma that is not addressed further in this review is work-exacerbated asthma. As recently reviewed, work-related exacerbation of asthma — ranging from single transient exacerbations after an unusual exposure to daily work-related worsening that can mimic occupational asthma — may occur in up to 25% of working persons with asthma.

Sensitizer-Induced Asthma

Occupational asthma can be caused by a specific workplace sensitizer, defined as an agent that induces asthma through a mechanism that is associated with a specific immunologic response. Occupational sensitizers are commonly high-molecular-weight agents (>10 kD, usually a protein or glycopeptide) that can cause production of specific IgE antibodies and typical allergic responses. Once a person is sensitized, very low exposures can induce asthma, which is often associated with rhinoconjunctivitis. Common examples are listed in Table 1. New causative agents are reported each year, and it would appear that almost any protein that becomes airborne and inhaled might be a potential cause of occupational asthma.

Low-molecular-weight occupational chemicals can also cause sensitization and, subsequently, asthma. A few have been associated with the production of specific IgE antibodies, such as complex platinum salts used in platinum refineries or the manufacture of catalysts, with a recent report of cases in workers exposed to platinum salts during the manufacture of cytotoxic drugs. Other examples include rhodium salts (used in electroplating); salts of nickel, chrome, and cobalt; acid anhydrides (used as hardeners in epoxy resins in chemical plants and in powder paints); and reactive dyes (used in textiles).

However, most low-molecular-weight chemical sensitizers induce asthma through mechanisms that are poorly understood, despite a phenotype suggesting sensitization. Diisocyanates are important sensitizers that are used in the production of rigid or flexible polyurethane foam; they are also used as hardeners in urethane spray paints and adhesives. Diisocyanates have been the most common cause of occupational asthma in many industrialized areas. Other examples of low-molecular-weight sensitizers are listed in Table 1. Most chemical sensitizers have highly reactive side chains.
Nonsensitizing, Irritant-Induced Occupational Asthma

Irritant-induced occupational asthma is a term used to describe occupational asthma that occurs from exposure to agents considered to be airway irritants, in the absence of sensitization. In 1985, diagnostic criteria for the reactive airways dysfunction syndrome, a severe form of irritant-induced asthma, were introduced (Table 2). Subsequent reports have modified the initial, stringent diagnostic criteria for this syndrome and use the term “irritant-induced asthma” to include cases with induced airway symptoms and an onset after one or more high-level exposures. This category also includes cases with less immediate responses to exposure (Table 2), with the recognition that these latter cases have less diagnostic certainty.

New-onset asthma after exposure to very high levels of alkaline dust from the collapse of the World Trade Center is generally accepted as a variant of irritant-induced asthma, despite the fact that many of those affected had a later onset of asthma symptoms than persons with the reactive airways dysfunction syndrome. At 1 year
As cleaning products and air fresheners,25-27 workers with an increased risk of asthma associated with exposure to irritants under usual work conditions include cleaners (domestic and industrial cleaners), nurses, textile workers, hog farmers, poultry workers, and aluminum potroom workers (in aluminum smelters).25-28 Thus, a spectrum of exposures leading to asthma seems likely, although asthma induced by exposure to low-level irritants cannot be reliably diagnosed in individual workers at present. Similarly, increased risks of asthma (in some cases with concomitant symptoms of bronchitis or with COPD) have been associated with irritant exposures without clear features of sensitization—for example, among entertainment workers, other farmers (with exposures to ammonia, endotoxins, and organic dusts associated with livestock), and motor vehicle operators.28

### Table 2. Features of Irritant-Induced Occupational Asthma.

<table>
<thead>
<tr>
<th>Criteria for RADS*</th>
<th>Modifications to Criteria for RADS†</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of new-onset asthma</td>
<td>History of new-onset asthma or recurrence of childhood asthma</td>
</tr>
<tr>
<td>Symptom onset related to a single high-level exposure (usually accidental)</td>
<td>Symptom onset related to one or more high-level exposures</td>
</tr>
<tr>
<td>Onset of symptoms ≤24 hr after exposure</td>
<td>Symptoms can begin ≥24 hr (in some reports, up to several days) after exposure</td>
</tr>
<tr>
<td>Exposure to a very high concentration of gas, fume, or spray with known irritant properties</td>
<td>List of exposures includes highly irritating dust (e.g., after the World Trade Center collapse)</td>
</tr>
<tr>
<td>Airway hyperresponsiveness or reversible airflow obstruction</td>
<td></td>
</tr>
<tr>
<td>Symptoms persistent for ≥3 mo</td>
<td>Previous airway disease associated with smoking or atopy may be difficult to rule out</td>
</tr>
<tr>
<td>No previous lower respiratory tract symptoms</td>
<td></td>
</tr>
</tbody>
</table>

* The criteria for the reactive airways dysfunction syndrome (RADS) were adapted from Brooks et al.18
† Patients were considered to have irritant-induced asthma in some studies with one or more of these modified criteria.5,19-21

**Epidemiology**

Occupational asthma has been reported in a minority of workers exposed to most known sensitizing agents (usually 10% or less among current workers in cross-sectional studies). In addition to the inherent sensitizing potency of a given agent in the workplace, the level of exposure influences the rate of sensitization, as shown with both high-molecular-weight sensitizers such as animal proteins (in persons who work with laboratory animals) and flour proteins (in bakers) and low-molecular-weight sensitizers such as diisocyanates.29 For example, workplaces with exposure to lower concentrations of diisocyanates have lower rates of occupational asthma.30 Predisposing or host factors among workers have included atopy (for most high-molecular-weight sensitizers),31 other genetic factors,32-33 and, possibly, smoking.34 None of these factors are sufficiently predictive to be used in determining the ability of a worker to participate in a job that carries a risk of sensitization.35

Population studies in a number of geographic regions have estimated the incidence and prevalence of occupational asthma caused by exposures to sensitizers and irritants. Although true geographic variation appears to be present, differences in study methods render comparisons difficult, as recently observed.36 A study involving almost 7000 participants in 13 countries used uniform methods to identify new-onset asthma...
and showed that the population attributable risk of occupational asthma was between 10 and 25%, equivalent to an incidence of 250 to 300 cases per 1 million people per year.\textsuperscript{37} Risks were increased among workers with known exposure to respiratory sensitizers. A systematic analysis of population attributable risk showed that an estimated 16.3\% of all cases of adult-onset asthma are caused by occupational exposure.\textsuperscript{38} There is a discrepancy between the rates of asthma diagnosed by a health professional as being work-related (4.7\% of all new asthma cases) and rates that include self-reported cases of work-related asthma (18.2\% of all new asthma cases)\textsuperscript{39}; one possible explanation for the difference is that occupational asthma is underrecognized in clinical practice.

Fewer studies have examined the prevalence or incidence of irritant-induced asthma with the use of the original criteria for the reactive airways dysfunction syndrome.\textsuperscript{18} A small study conducted after glacial acetic acid was spilled in a hospital\textsuperscript{40} showed a clear exposure–response relationship: the incidence of asthma was highest among those with the greatest exposure (four of nine persons without previous respiratory symptoms). An association with the level of exposure was also found for the development of respiratory sensitizers. A systematic analysis of companies or precedes lower respiratory symptoms, especially when high-molecular-weight agents incite the asthma.\textsuperscript{6} Although a thorough clinical and occupational history must be obtained, a compatible history alone is insufficient for diagnosis and has a low positive predictive value.\textsuperscript{42} Investigations should be started as soon as the diagnosis is suspected, preferably while the patient is still working, and should be as comprehensive as feasible, including assessment of clinical symptoms, objective confirmation of asthma, testing for skin or serologic specific IgE antibodies when possible, and documentation of symptomatic, functional, and inflammatory changes in response to exposure to occupational agents (at work vs. away from work or by specific challenge). Each test has limitations that may be overcome by combining several tests.\textsuperscript{43} A suggested diagnostic approach is summarized in Figure 2, and further advice is detailed in a North American consensus statement\textsuperscript{6} and European guidelines.\textsuperscript{44,45} Detailed information about tests and their practical limitations and advantages is available in the Supplementary Appendix, including Table S1.
Irritant-Induced Asthma

Diagnosis of irritant-induced asthma relies on a suggestive clinical history along with the demonstration of airflow limitation or airway hyperresponsiveness. The diagnostic criteria are described in Table 2.

PREVENTION AND MANAGEMENT

Sensitizer-Induced Asthma

Primary, secondary, and tertiary preventive measures may reduce the incidence and severity of sensitizer-induced asthma (Table 3). Primary prevention aims to prevent sensitization to work-
**Figure 2. Algorithm for Evaluating an Adult with Asthmalike Symptoms for Sensitizer-Induced Occupational Asthma.**

This algorithm is adapted from Tarlo et al. Information on the advantages and limitations of individual tests is available in the Supplementary Appendix and in published guidelines and consensus statements. PEF denotes peak expiratory flow.
Monitor the patient’s asthma in future work locations to ensure safe exposure (efficacy as primary prevention currently theoretical).

Avoid use of known sensitizing agents if safer alternatives are available.

Modify the physical or chemical form of known sensitizers to reduce risk of exposure (e.g., less volatile preparations, polymerized products, and latex gloves with a low-protein and low-powder content).

Reduce exposure to work sensitizers by means of occupational hygiene measures (e.g., use of robotics, containment, ventilation, and respirators).

Educate workers in the use of safe practices at work.

Monitor and control levels of exposure to workplace sensitizers.

Secondary prevention (early detection)

Institute medical-surveillance programs for workers at risk, consisting of preplacement and periodic respiratory questionnaires, with spirometry and immunologic tests as indicated.

Ensure that health care providers have adequate knowledge of occupational asthma and consider it early in the evaluation of all adults with asthma symptoms, leading to early diagnosis and management of occupational asthma.

Educate workers about the risks of occupational asthma through workplace education programs and knowledge about preventive measures in the workplace. The model is based on the observation that most sensitizing chemicals, as compared with nonsensitizing chemicals, have a greater number of reactive or functional groups and are more likely to have unsaturated bonds containing carbon and nitrogen heteroatoms. Unfortunately, many sensitizers cannot be readily replaced with nonsensitizing agents (e.g., flour in bakeries). However, a reduction in exposure (inhahalational exposure and possibly also skin exposure) to a respiratory sensitizer can reduce the proportion of workers who become sensitized, as was shown when airborne exposure to latex proteins was reduced by introducing latex gloves with a low-powder and low-protein content. Therefore, efforts have been made to reduce exposure to respiratory sensitizers by instituting occupational hygiene measures such as containment, improved ventilation, and (as a last option) the use of personal protective equipment, as well as worker education to enhance adherence to recommended measures.

Examples in which one or more of these measures have been effective include encapsulation of enzymes in the detergent industry, reduced exposure to laboratory animals (by means of engineering and procedural changes and the use of appropriate respiratory and protective devices and skin covering), and simple methods of worker education to reduce exposure in bakeries. However, even in occupations with a well-recognized risk of sensitization, such as work involving laboratory animals, implementation of and knowledge about preventive measures in the workplace has been suboptimal.

For diisocyanates, changes that may reduce the risk of sensitization include the formulation of less volatile compounds, the use of polymeric rather than monomeric diisocyanates, the use of robotics in some industrialized settings, monitoring of exposure concentrations to ensure that they are below recommended threshold levels, and action plans to manage unintended high-level exposures. Such measures, in conjunction with secondary preventive action, have been associated with reduced rates of sensitization and occupational asthma, according to a report from Ontario, Canada.

Secondary prevention includes early identification of workers with occupational exposure to asthma-causing agents by means of medical surveillance (periodic respiratory questionnaires with or without spirometry and immunologic tests) and further investigations to confirm diagnosis and then remove the person from further exposure. Such measures have been introduced in some companies for at-risk workers — for example, persons who work in bakeries;
those who work with animals, detergents, diisocyanates, or complex platinum salts; and epoxy workers exposed to acid anhydrides. Studies suggest that such programs are beneficial, albeit the benefit is difficult to specify precisely because of the multicomponent nature of the programs. It has been suggested that the questionnaire component is likely to be most predictive among bakers but may be less reliable among respondents who believe that their answers might result in job loss.

Asthma symptoms and airway hyperresponsiveness persist in approximately 70% of patients with occupational asthma, even several years after removal from the offending environment. Outcomes are best when the diagnosis is established early, the exposure is stopped, and the asthma is not yet severe. Appropriate management after diagnosis, in addition to prevention of further exposure when possible, involves tertiary prevention with pharmacologic management that follows clinical-practice guidelines.

Recent systematic reviews indicate that complete and definitive avoidance of exposure to the causal agent remains the preferred approach to the management of immunologic occupational asthma. Although reduction of exposure to the agent can be considered an alternative to complete avoidance of exposure, the limited available evidence indicates that reduced exposure is less beneficial than exposure cessation.

Immunotherapy has been tested for a few sensitizing agents with IgE-dependent reactions, mainly in health care workers who were allergic to latex but also in small numbers of workers who were allergic to cereal, sea squirt (Hoya asthma), and laboratory animals. Although immunotherapy can reduce cutaneous and respiratory symptoms, systemic reactions often occur. Whether asthma outcomes are altered in the long term remains to be determined, and further studies are needed before immunotherapy can be recommended. Improvement with the monoclonal anti-IgE antibody omalizumab has been reported in a few patients with occupational asthma who remained exposed to the causal agent, but it also requires further prospective studies.

Irritant-Induced Asthma

There is less information on the prevention of irritant-induced asthma than on the prevention of sensitizer-induced asthma, since the most straightforward cases of irritant-induced asthma are due to accidental exposure. Prevention should include occupational-hygiene measures that ensure the safety of workers in environments where there is the potential for accidental exposure to irritants. General measures include containment, good ventilation, worker education regarding safety practices, and, when other measures are not sufficient, use of fit-tested respiratory protective devices.

### CONCLUSIONS

Occupational asthma is potentially preventable in most cases. Furthermore, an improved understanding of occupational asthma may enhance our knowledge about other types of asthma. To minimize the risk of long-term impairment from occupational asthma, health care practitioners should consider this diagnosis early in their evaluation of adults with symptoms of asthma.

Dr. Tarlo reports receiving consulting fees for worker assessments, expert testimony, or both from SOMA Medical Assessments, Graydon Sheppard Professional Corporation, and Barrick Gold and grant support through her institution from AllerGen. Dr. Lemiere reports receiving consulting fees, lecture fees, and payment for the development of educational presentations from AstraZeneca; consulting fees and lecture fees from Merck; and lecture fees, as well as grant support through her institution, from GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Dr. James Martin from the Department of Medicine, McGill University, Montreal, for helpful review of an earlier version of Figure 1.

Copyright © 2014 Massachusetts Medical Society.